Loading...
Market
What will be identified as the primary reason for CagriSema's failure in future analyses by end of 2025?
2
Resolution / Starting Odds
Ineffective dosage • 25%
Patient non-compliance • 25%
Adverse side effects • 25%
Other • 25%
Scientific publications and Novo Nordisk's official reports
Story
Novo Nordisk Shares Drop 27% as CagriSema Misses Weight Loss Target in Phase 3 Trial
Dec 20, 2024, 11:00 AM
Novo Nordisk, Europe's largest company, saw its shares plummet by up to 27%, marking its worst trading day since April 2002, after its experimental obesity drug CagriSema failed to meet weight loss expectations in the Phase 3 REDEFINE 1 trial. The trial showed that patients treated with CagriSema achieved a 22.7% weight reduction after 68 weeks, falling short of the anticipated 25%. Additionally, only 57% of patients reached the highest dose after 68 weeks. Comparatively, patients receiving semaglutide 2.4 mg and cagrilintide 2.4 mg experienced weight losses of 16.1% and 11.8%, respectively, while the placebo group lost 2.3%. The disappointing results led to a significant sell-off, with the stock losing its 200-day moving average at $125 and trading 48% below its June high. Competitors such as Eli Lilly and Viking Therapeutics saw their shares rise in response to the news.
View original story
Similar markets
Technical malfunction • 25%
Design flaw • 25%
Human error • 25%
Other • 25%
Mental health system failure • 25%
Criminal justice system failure • 25%
Combination of both systems • 25%
Other factors • 25%
Political Climate • 25%
Economic Factors • 25%
Environmental Concerns • 25%
Technical Challenges • 25%
Achieve target weight loss in all regions • 25%
Achieve target weight loss in some regions • 25%
No region achieves target weight loss • 25%
Trials discontinued • 25%
European Union regulations • 25%
Microsoft's internal error • 25%
Crowdstrike involvement • 25%
Other • 25%
Technical malfunction • 25%
Human error • 25%
External factors • 25%
Other • 25%
Internal miscommunication • 25%
Resource limitations • 25%
Procedural failures • 25%
Other reason • 25%
Production scaling issues • 25%
Quality control problems • 25%
Financial mismanagement • 25%
Market competition • 25%
School Counselor • 25%
School Administration • 25%
Law Enforcement • 25%
No one held responsible • 25%
Cost • 25%
Effectiveness • 25%
Environmental impact • 25%
Other • 25%
Economic Concerns • 25%
Political Opposition • 25%
Voter Turnout • 25%
Campaign Strategies • 25%
Image realism issues • 25%
Text rendering issues • 25%
Artifact presence • 25%
Other • 25%